Inside every human cell lies a remarkable act of genetic thrift: a single antiviral gene that produces not one protein defender, but two—each capable of neutralizing viruses that seem worlds apart. Researchers at the MRC-University of Glasgow Center for Virus Research have discovered that the gene OAS2 achieves something that sounds like nature's version of "buy one, get one free," expanding the immune system's antiviral arsenal through an elegantly simple trick.
The two protein versions, called isoforms, are 95 percent identical twins separated by a single difference: a tiny, flexible tail that measures just 4 amino acids in one version and 36 amino acids in the other. Despite this modest variation in a protein composed of 683 amino acids, the consequences are dramatic. One version targets Cardiovirus A, also known as encephalomyocarditis virus (EMCV), which can inflame the heart and brain. The other inhibits a common cold coronavirus that is a close relative of the virus responsible for COVID-19.
What makes this discovery remarkable is not just that one gene does the work of two—it's that these fraternal protein twins fight their respective viral opponents using entirely different molecular mechanisms. The researchers found that despite their similarity, the two isoforms deploy unique sets of molecular "tools" to shut down viral replication. Scientists are still working to identify exactly what those distinct strategies are, but the finding itself speaks to how evolution has engineered redundancy and versatility into a single genetic instruction.
The implications ripple beyond pure biology. Mutations in OAS2 and related antiviral genes can shift a person's vulnerability to viral infections—sometimes with severe consequences when new pathogens emerge. During the COVID-19 pandemic, researchers noticed that people carrying mutations in the related OAS1 gene faced increased likelihood of developing severe disease. Understanding how these genes work at the molecular level could eventually help explain why some individuals fall gravely ill while others weather the same infection more lightly.
Dr. Emma Davies, who co-led the study now published in The EMBO Journal, captured the surprise at the heart of their discovery: "What really surprised us was that two forms of a protein, differing only by a tiny region, were able to inhibit completely different viruses in completely different ways." Her colleague Dr. Adam Fletcher added perspective on the broader significance. "The antiviral gene OAS2 provides a great example of how this process expands functional diversity from a single gene—a sort of 'Buy One, Get One Free' for the immune response."
The human genome contains hundreds of antiviral genes that activate when viruses breach cell defenses. Viruses, though, evolve faster than humans do, and many have evolved or even stolen genes from their animal hosts that counteract our immune machinery. Yet this new research suggests that evolution has equipped us with more cleverness than we might have assumed—the ability to multiply our defenses without multiplying our genes. As novel viruses continue to emerge, understanding how a single gene can accomplish multiple defensive roles becomes not just scientifically interesting, but practically urgent.